{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:06:00Z","timestamp":1648901160304},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s11899-007-0011-5","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T10:12:52Z","timestamp":1177927972000},"page":"75-82","source":"Crossref","is-referenced-by-count":6,"title":["BCR-ABL-negative chronic myeloid leukemia"],"prefix":"10.1007","volume":"2","author":[{"given":"Sonja","family":"Burgstaller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,5,1]]},"reference":[{"key":"11_CR1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"J.W. Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292\u20132302.","journal-title":"Blood"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/beha.2001.0154","volume":"14","author":"A. Chase","year":"2001","unstructured":"Chase A, Huntly BJ, Cross NCP: Cytogenetics of chronic myeloid leukaemia. Best Pract Res Clin Haematol 2001, 14:553\u2013571.","journal-title":"Best Pract Res Clin Haematol"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","volume":"95","author":"F. Onida","year":"2002","unstructured":"Onida F, Ball G, Kantarjian HM, et al.: Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia. Cancer 2002, 95:1673\u20131684.","journal-title":"Cancer"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","volume":"107","author":"E.J. Steer","year":"2002","unstructured":"Steer EJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor-\u03b2. Acta Haematol 2002, 107:113\u2013122.","journal-title":"Acta Haematol"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","volume":"11","author":"E.J. Baxter","year":"2002","unstructured":"Baxter EJ, Hochhaus A, Bolufer P, et al.: The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet 2002, 11:1391\u20131397.","journal-title":"Hum Mol Genet"},{"key":"11_CR6","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1038\/sj.onc.1206543","volume":"22","author":"P. Trempat","year":"2003","unstructured":"Trempat P, Villalva C, Laurent G, et al.: Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: A new clinical target for STI571\/Glivec. Oncogene 2003, 22:5702\u20135706.","journal-title":"Oncogene"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J. Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201\u20131214.","journal-title":"N Engl J Med"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","volume":"100","author":"J.H. Griffin","year":"2003","unstructured":"Griffin JH, Leung J, Bruner RJ, et al.: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003, 100:7830\u20137835.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","volume":"20","author":"J. Score","year":"2006","unstructured":"Score J, Curtis C, Waghorn K, et al.: Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827\u2013832.","journal-title":"Leukemia"},{"key":"11_CR10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","volume":"30","author":"A. Pardanani","year":"2006","unstructured":"Pardanani A, Ketterling RP, Li CY, et al.: FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 2006, 30:965\u2013970.","journal-title":"Leuk Res"},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/gcc.20359","volume":"45","author":"C. Walz","year":"2006","unstructured":"Walz C, Curtis C, Schnittger S, et al.: Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 2006, 45:950\u2013956.","journal-title":"Genes Chromosomes Cancer"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1073\/pnas.0601192103","volume":"103","author":"E.H. Stover","year":"2006","unstructured":"Stover EH, Chen J, Folens C, et al.: Activation of FIP1L1-PDGFR\u03b1 requires disruption of the juxtamembrane domain of PDGFR\u03b1 and is FIP1L1-independent. Proc Natl Acad Sci U S A 2006, 103:8078\u20138083.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2003-04-1150","volume":"102","author":"K. Wilkinson","year":"2003","unstructured":"Wilkinson K, Velloso ER, Lopes LF, et al.: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood 2003, 102:4187\u20134190.","journal-title":"Blood"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-03-4026","volume":"64","author":"C. Morerio","year":"2004","unstructured":"Morerio C, Acquila M, Rosanda C, et al.: HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). Cancer Res 2004, 64:2649\u20132651.","journal-title":"Cancer Res"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/0008-5472.CAN-04-0144","volume":"64","author":"J.L. Vizmanos","year":"2004","unstructured":"Vizmanos JL, Novo FJ, Rom\u00e1n JP, et al.: NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Cancer Res 2004, 64:2673\u20132676.","journal-title":"Cancer Res"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.leu.2403548","volume":"19","author":"R.L. Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Sternberg DW, et al.: KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Leukemia 2005, 19:27\u201330.","journal-title":"Leukemia"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"7216","DOI":"10.1158\/0008-5472.CAN-04-2005","volume":"64","author":"F.H. Grand","year":"2004","unstructured":"Grand FH, Burgstaller S, Kuhr T, et al.: p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer Res 2004, 64:7216\u20137219.","journal-title":"Cancer Res"},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/sj.leu.2404307","volume":"20","author":"R. Rosati","year":"2006","unstructured":"Rosati R, La Starza R, Luciano L, et al.: TPM3\/PDGFRB fusion transcript and its reciprocal in chronic eosinophilic leukaemia. Leukemia 2006, 20:1623\u20131624.","journal-title":"Leukemia"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V90.11.4271","volume":"90","author":"A. Abe","year":"1997","unstructured":"Abe A, Emi N, Tanimoto M, et al.: Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution. Blood 1997, 90:4271\u20134277.","journal-title":"Blood"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","volume":"109","author":"M. David","year":"2007","unstructured":"David M, Cross NCP, Burgstaller S, et al.: Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL -negative chronic myeloproliferative disorders. Blood 2007, 109:61\u201364.","journal-title":"Blood"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000085559","volume":"114","author":"J. Gotlib","year":"2005","unstructured":"Gotlib J: Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005, 114:7\u201325.","journal-title":"Acta Haematol"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0145-2126(84)90013-4","volume":"8","author":"J.P. Vannier","year":"1984","unstructured":"Vannier JP, Bizet M, Bastard C, et al.: Simultaneous occurrence of a T-cell lymphoma and a chronic myelogenous leukemia with an unusual karyotype. Leuk Res 1984, 8:647\u2013657.","journal-title":"Leuk Res"},{"key":"11_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","volume":"107","author":"D. Macdonald","year":"2002","unstructured":"Macdonald D, Reiter A, Cross NCP: The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1 [review]. Acta Haematol 2002, 107:101\u2013107.","journal-title":"Acta Haematol"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","volume":"85","author":"R.C. Inhorn","year":"1995","unstructured":"Inhorn RC, Aster JC, Roach SA, et al.: A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995, 85:1881\u20131887.","journal-title":"Blood"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2002-02-0577","volume":"101","author":"G. Guasch","year":"2003","unstructured":"Guasch G, Popovici C, Mugneret F, et al.: Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood 2003, 101:286\u2013288.","journal-title":"Blood"},{"key":"11_CR26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/gcc.20144","volume":"42","author":"E. Belloni","year":"2005","unstructured":"Belloni E, Trubia M, Gasparini P, et al.: 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 2005, 42:320\u2013325.","journal-title":"Genes Chromosomes Cancer"},{"key":"11_CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.20023","volume":"40","author":"E.K. Grand","year":"2003","unstructured":"Grand EK, Grand FH, Chase AJ, et al.: Identification of a novel gene, FGFR1OP2, fused to FGFR1 in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 2003, 40:78\u201383.","journal-title":"Genes Chromosomes Cancer"},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2403712","volume":"19","author":"C. Walz","year":"2005","unstructured":"Walz C, Chase A, Schoch C, et al.: The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia 2005, 19:1005\u20131009.","journal-title":"Leukemia"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V98.13.3778","volume":"98","author":"A. Demiroglu","year":"2001","unstructured":"Demiroglu A, Steer EJ, Heath C, et al.: The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1 : transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001, 98:3778\u20133783.","journal-title":"Blood"},{"key":"11_CR30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.thj.6200561","volume":"5","author":"J.L. Vizmanos","year":"2004","unstructured":"Vizmanos JL, Hernandez R, Vidal MJ, et al.: Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J 2004, 5:534\u2013537.","journal-title":"Hematol J"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1535-6108(04)00053-4","volume":"5","author":"S. Roumiantsev","year":"2004","unstructured":"Roumiantsev S, Krause DS, Neumann CA, et al.: Distinct stem cell myeloproliferative\/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287\u2013298.","journal-title":"Cancer Cell"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1309\/JT5BE2L1FGG8P8Y6","volume":"126","author":"P. Lin","year":"2006","unstructured":"Lin P, Jones D, Medeiros LJ, et al.: Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 2006, 126:530\u2013533.","journal-title":"Am J Clin Pathol"},{"key":"11_CR33","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","volume":"20","author":"H.A. Vu","year":"2006","unstructured":"Vu HA, Xinh PT, Masuda M, et al.: FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006, 20:1414\u20131421.","journal-title":"Leukemia"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","volume":"278","author":"V. Lacronique","year":"1997","unstructured":"Lacronique V, Boureux A, Valle VD, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309\u20131312.","journal-title":"Science"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","volume":"90","author":"P. Peeters","year":"1997","unstructured":"Peeters P, Raynaud SD, Cools J, et al.: Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535\u20132540.","journal-title":"Blood"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","volume":"65","author":"A. Reiter","year":"2005","unstructured":"Reiter A, Walz C, Watmore A, et al.: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662\u20132667.","journal-title":"Cancer Res"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","volume":"44","author":"F. Griesinger","year":"2005","unstructured":"Griesinger F, Hennig H, Hillmer F, et al.: A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer 2005, 44:329\u2013333.","journal-title":"Genes Chromosomes Cancer"},{"key":"11_CR38","volume-title":"SEER Cancer Statistic Review, 1975\u20132000","author":"L.A.G. Ries","year":"2003","unstructured":"Ries LAG, Eisner MP, Kosary CL: SEER Cancer Statistic Review, 1975\u20132000. Bethesda, MD: National Cancer Institute; 2003."},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","volume":"106","author":"A.V. Jones","year":"2005","unstructured":"Jones AV, Kreil S, Zoi K, et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162\u20132168.","journal-title":"Blood"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"D.P. Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, et al.: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes. Blood 2005, 106:1207\u20131209.","journal-title":"Blood"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J. Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, et al.: JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370\u20133373.","journal-title":"Blood"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2006-06-026666","volume":"108","author":"T.L. Gu","year":"2006","unstructured":"Gu TL, Goss VL, Reeves C, et al.: Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood 2006, 108:4202\u20134204.","journal-title":"Blood"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","volume":"19","author":"R. Kurzrock","year":"2001","unstructured":"Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al.: BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001, 19:2915\u20132926.","journal-title":"J Clin Oncol"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","volume":"101","author":"J. Chen","year":"2004","unstructured":"Chen J, DeAngelo DJ, Kutok JL, et al.: PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004, 101:14479\u201314484.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR45","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M. Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531\u20132541.","journal-title":"N Engl J Med"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542\u20132551.","journal-title":"N Engl J Med"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","volume":"106","author":"E.H. Stover","year":"2005","unstructured":"Stover EH, Chen J, Lee BH, et al.: The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR\u03b2 and FIP1L1-PDGFR\u03b1 in vitro and in vivo. Blood 2005, 106:3206\u20133213.","journal-title":"Blood"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","volume":"108","author":"E. Lierman","year":"2006","unstructured":"Lierman E, Folens C, Stover EH, et al.: Sorafenib (BAY 43-9006) is a potent inhibitor of FIP1L1-PDGFRA and the imatinib resistant FIP1L1-PDGFRA T674I mutant. Blood 2006, 108:1374\u20131376.","journal-title":"Blood"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.beha.2005.07.001","volume":"19","author":"A. Tefferi","year":"2006","unstructured":"Tefferi A, Gilliland G: Classification of chronic myeloid disorders: From Dameshek towards a semi-molecular system. Best Pract Res Clin Haematol 2006, 19:365\u2013385.","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-007-0011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-007-0011-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T15:56:15Z","timestamp":1587484575000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-007-0011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11899-007-0011-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}